Gilead’s Truvada Defense Misunderstands Antitrust Law, FTC Says

October 30, 2019

The Federal Trade Commission says Gilead Sciences Inc. is on the wrong side of a key issue in a Northern District of California lawsuit claiming it schemed to maintain the market “stranglehold” enjoyed by its blockbuster HIV drug Truvada.